Covid-19 Update Debate
Full Debate: Read Full DebateCaroline Johnson
Main Page: Caroline Johnson (Conservative - Sleaford and North Hykeham)Department Debates - View all Caroline Johnson's debates with the Department of Health and Social Care
(3 years, 3 months ago)
Commons ChamberI do not disagree with the hon. Lady; I know what she is talking about. She will have seen the interim advice from the JCVI on phase 1, which is for categories 1 to 4, and phase 2, which is for categories 5 to 9—including category 6, the largest category of those people she describes. The JCVI has yet to deliver its final advice post the cov-boost study data. As we have done throughout the deployment, we will follow the JCVI advice.
The JCVI has assessed the known risks and benefits of the covid vaccine for 12 to 15-year-olds and has not recommended it. As the Minister said, the Health Secretary has now referred the matter to the chief medical officers so that they can look at it from a so-called “broader perspective”. Now that children are attending school, half of them have had covid already, they do not need to isolate unless they test positive and they do not need to isolate if they are merely a contact, does the Minister agree that disruption to education will now be much less severe? Furthermore, does he agree that it is not reasonable to use political decisions about schools as leverage to force vaccines on a population of children?
I am grateful for my hon. Friend’s very thoughtful question. I can reassure her that there is no political decision making; the process that the chief medical officers are undertaking is unencumbered by any political motivation whatsoever. We will absolutely follow their advice, and the JCVI is in the room as they are deliberating. It is important to recall that the JCVI advice was that vaccination is marginally more beneficial to healthy 12 to 15-year olds than non-vaccination, but not enough to recommend a universal vaccination programme. It is also worth reminding the House that we have been vaccinating 12 to 15-year-olds who are more vulnerable to serious infection and hospitalisation, as the JCVI recommended.